Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387020178> ?p ?o ?g. }
- W4387020178 abstract "Abstract Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiovascular-induced adverse events such as heart failure, hypertension, ischemic heart disease, arrhythmias, thromboembolic events, and hemorrhage remain a major complication. The European society of cardiology address that concern with antineoplastic monoclonal antibodies issuing a guideline to manage and monitor chemotherapy-induced cardiotoxicity. There is limited evidence of the real-world prevalence of cardiovascular (CV) events induced by monoclonal antibodies among patients with cancer in Saudi Arabia. Objective To evaluate the prevalence of cardiovascular adverse events among patients with cancer treated with monoclonal antibodies in Saudi Arabia. Methods This is a retrospective study conducted in a tertiary care hospital, Riyadh, Saudi Arabia. Data were obtained from an electronic medical record of patients with cancer treated with one of the selected monoclonal antibodies, who met the inclusion criteria between January 2005 until June 2015 and have been followed up for at least one year. Patients were stratified into groups according to monoclonal antibodies treatment: trastuzumab, bevacizumab, pertuzumab, and combined mAbs. Results A total of 1067 patient were included in the study, within the pre-determined study period. The prevalence of cardiovascular disease among patients with cancer treated with monoclonal antibodies was 16.3%. The prevalence of heart failure was relatively higher in the trastuzumab group (46/626 patients, 7.3%). Among 418 patients treated with bevacizumab, hypertension was the most frequent adverse event, reported in 38 patients (9.1%), followed by thromboembolism reported in 27 patients (6.5%). Treatment discontinuation owing to cardiovascular adverse events was reported in 42/1,067 patients (3.9%). Conclusion and relevance Prevalence of antineoplastic monoclonal antibody induced cardiovascular adverse events among patients with cancer is substantially high in Saudi Arabia. There is an urgent need to streamline the practice for identifying high risk patients and flexible referral system for cardio-oncology care." @default.
- W4387020178 created "2023-09-26" @default.
- W4387020178 creator A5005101409 @default.
- W4387020178 creator A5006354104 @default.
- W4387020178 creator A5035845099 @default.
- W4387020178 creator A5060468670 @default.
- W4387020178 creator A5080284159 @default.
- W4387020178 creator A5092936174 @default.
- W4387020178 creator A5092936175 @default.
- W4387020178 creator A5092936176 @default.
- W4387020178 date "2023-09-25" @default.
- W4387020178 modified "2023-10-16" @default.
- W4387020178 title "Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system" @default.
- W4387020178 cites W1684140257 @default.
- W4387020178 cites W1944375371 @default.
- W4387020178 cites W2048818094 @default.
- W4387020178 cites W2049302115 @default.
- W4387020178 cites W2054915645 @default.
- W4387020178 cites W2067978628 @default.
- W4387020178 cites W2099382677 @default.
- W4387020178 cites W2105184616 @default.
- W4387020178 cites W2110688110 @default.
- W4387020178 cites W2111790572 @default.
- W4387020178 cites W2113832885 @default.
- W4387020178 cites W2118447251 @default.
- W4387020178 cites W2121785313 @default.
- W4387020178 cites W2134531925 @default.
- W4387020178 cites W2139927762 @default.
- W4387020178 cites W2141056749 @default.
- W4387020178 cites W2146855795 @default.
- W4387020178 cites W2153628956 @default.
- W4387020178 cites W2157769714 @default.
- W4387020178 cites W2170928115 @default.
- W4387020178 cites W2178738676 @default.
- W4387020178 cites W2336891733 @default.
- W4387020178 cites W2409660854 @default.
- W4387020178 cites W2467192828 @default.
- W4387020178 cites W2497876789 @default.
- W4387020178 cites W2510659316 @default.
- W4387020178 cites W2615421777 @default.
- W4387020178 cites W2623460738 @default.
- W4387020178 cites W2742019806 @default.
- W4387020178 cites W2742729000 @default.
- W4387020178 cites W2750979344 @default.
- W4387020178 cites W2793069147 @default.
- W4387020178 cites W2809398726 @default.
- W4387020178 cites W2810465105 @default.
- W4387020178 cites W2891599706 @default.
- W4387020178 cites W2899118293 @default.
- W4387020178 cites W2917216229 @default.
- W4387020178 cites W2958119318 @default.
- W4387020178 cites W2980271263 @default.
- W4387020178 cites W2999536665 @default.
- W4387020178 cites W3013347515 @default.
- W4387020178 cites W3066083631 @default.
- W4387020178 cites W3088519233 @default.
- W4387020178 cites W4283772666 @default.
- W4387020178 cites W4293217929 @default.
- W4387020178 cites W4310566600 @default.
- W4387020178 doi "https://doi.org/10.1186/s40959-023-00184-z" @default.
- W4387020178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37749652" @default.
- W4387020178 hasPublicationYear "2023" @default.
- W4387020178 type Work @default.
- W4387020178 citedByCount "0" @default.
- W4387020178 crossrefType "journal-article" @default.
- W4387020178 hasAuthorship W4387020178A5005101409 @default.
- W4387020178 hasAuthorship W4387020178A5006354104 @default.
- W4387020178 hasAuthorship W4387020178A5035845099 @default.
- W4387020178 hasAuthorship W4387020178A5060468670 @default.
- W4387020178 hasAuthorship W4387020178A5080284159 @default.
- W4387020178 hasAuthorship W4387020178A5092936174 @default.
- W4387020178 hasAuthorship W4387020178A5092936175 @default.
- W4387020178 hasAuthorship W4387020178A5092936176 @default.
- W4387020178 hasBestOaLocation W43870201781 @default.
- W4387020178 hasConcept C121608353 @default.
- W4387020178 hasConcept C126322002 @default.
- W4387020178 hasConcept C143998085 @default.
- W4387020178 hasConcept C159654299 @default.
- W4387020178 hasConcept C197934379 @default.
- W4387020178 hasConcept C203014093 @default.
- W4387020178 hasConcept C2776694085 @default.
- W4387020178 hasConcept C2777802072 @default.
- W4387020178 hasConcept C2778198053 @default.
- W4387020178 hasConcept C2778233292 @default.
- W4387020178 hasConcept C2779134260 @default.
- W4387020178 hasConcept C2779786085 @default.
- W4387020178 hasConcept C2781164504 @default.
- W4387020178 hasConcept C530470458 @default.
- W4387020178 hasConcept C542903549 @default.
- W4387020178 hasConcept C71924100 @default.
- W4387020178 hasConceptScore W4387020178C121608353 @default.
- W4387020178 hasConceptScore W4387020178C126322002 @default.
- W4387020178 hasConceptScore W4387020178C143998085 @default.
- W4387020178 hasConceptScore W4387020178C159654299 @default.
- W4387020178 hasConceptScore W4387020178C197934379 @default.
- W4387020178 hasConceptScore W4387020178C203014093 @default.
- W4387020178 hasConceptScore W4387020178C2776694085 @default.
- W4387020178 hasConceptScore W4387020178C2777802072 @default.
- W4387020178 hasConceptScore W4387020178C2778198053 @default.
- W4387020178 hasConceptScore W4387020178C2778233292 @default.